Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

48
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
48
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

41
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
41

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MAPPING THE MTOR PATHWAY IN LUNG TRANSPLANTATION: IS IT TIME FOR A BIOMARKER-DRIVEN PRECISION THERAPY?

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Outcomes of staged single versus bilateral lung transplantation in the modern era.

JTCVS open·2026
Same author

Liver disease severity score predicts early and late mortality after lung transplantation: A United Network for Organ Sharing database analysis.

JTCVS open·2026
Same author

Disseminated Acanthamoeba Infection After Heart-Lung Transplantation.

Transplant infectious disease : an official journal of the Transplantation Society·2026
Same author

Lung Transplantation in People Living With HIV With Absolute CD4+ T Cell Counts Under 200 Cells per Microliter.

Transplant infectious disease : an official journal of the Transplantation Society·2025
Same author

Acoustofluidic system for targeted antibody removal in transplantation: Enabling small-volume therapeutic apheresis.

Science advances·2025

Related Experiment Video

Updated: Aug 6, 2025

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.4K

Screening and Management of PTLD.

Lorenzo Zaffiri1, Eileen T Chambers2

  • 1Division of Pulmonary and Critical Care Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.

Transplantation
|March 23, 2023
PubMed
Summary

Posttransplant lymphoproliferative disorder (PTLD) is a serious complication after transplants. Early risk evaluation using Epstein-Barr virus status and load is crucial for personalized PTLD management and improved outcomes.

More Related Videos

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm
08:12

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

12.0K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

195

Related Experiment Videos

Last Updated: Aug 6, 2025

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.4K
Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm
08:12

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

12.0K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

195

Area of Science:

  • Immunology
  • Oncology
  • Transplantation Medicine

Background:

  • Posttransplant lymphoproliferative disorder (PTLD) is a severe complication following organ and stem cell transplantation.
  • PTLD occurs in immunosuppressed patients and has a high mortality rate (up to 50%).

Purpose of the Study:

  • To review current screening and treatment strategies for PTLD.
  • To propose a risk stratification approach for PTLD development.
  • To discuss evolving therapeutic options for PTLD.

Main Methods:

  • Review of existing literature on PTLD screening and treatment.
  • Analysis of risk factors including Epstein-Barr virus (EBV) serostatus and viral load.
  • Evaluation of current and emerging therapeutic modalities.

Main Results:

  • Personalized risk assessment for PTLD is essential.
  • EBV serostatus and viral load are key determinants of PTLD risk.
  • Diverse pathological features necessitate varied treatment approaches.

Conclusions:

  • A proactive screening strategy based on EBV markers can identify high-risk transplant recipients.
  • Current treatments for PTLD are evolving, with new cell-based therapies showing promise.
  • Timely intervention and personalized management are critical for improving PTLD patient survival.